You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

433 Results
Document
Dec 1969
Document
Dec 1969
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Exceptional Access Program
    acalabrutinib - In Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma, based on criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
bendamustine,
acalabrutinib,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Jan 2026
Guidelines and Advice
Status: In-Review
ID: 2-29
Version: 4
Dec 1969
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
nab-PACLitaxel,
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Jan 2026
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
nab-PACLitaxel,
PERTuzumab (Unfunded),
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
New
Jan 2026
Senior Scientist, Indigenous Cancer Care Unit, Acute and Hospital-Based Care, Ontario Health Lead Scientist amanda.sheppard@ontariohealth.ca
Senior chercheuse, Unité des soins de cancérologie chez les peuples autochtones, Soins aigus et hospitaliers, Santé Ontario Chercheuse...
Drug
Other Name(s): Efudex® Cream , IV generic brands available
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
cetuximab (Unfunded),
irinotecan,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Jan 2026

Pages